Portfolio: Warburg Pincus and HTDK Group
Warburg Pincus’ investment in Chinese medical devices industry services provider HTDK Group is riding the domestic healthcare wave. Bringing foreigners to the party is the next chapter
By 2018, Switzerland-headquartered conglomerate DKSH Group was shifting its Asian priorities away from China and healthcare. The company had long since divested its pharmaceuticals assets and was looking...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.